Remarks

• The GDG considered in vitro data demonstrating that neutralization of currently circulating variants of SARS-CoV-2 and their subvariants with sotrovimab is diminished.
• There was consensus among the panel that the meaningful reduction of in vitro neutralization activity strongly suggests absence of clinical effectiveness of monoclonal antibodies such as sotrovimab.
• There was also consensus regarding the need for clinical trial evidence in order to confirm clinical effectiveness of new monoclonal antibodies that reliably neutralize circulating strains in vitro.